What to expect from HER-2 directed therapies in advanced gastric cancer?

Home Page
About
Submit A Journal
Submit A Conference
Submit Paper/Book
- Submit a Preprint
- Submit a Book
Contact

Marmara Medical Journal
Special Issue:1: Oncology Special Issue
What to expect from HER-2 directed therapies in advanced gastric cancer?

What to expect from HER-2 directed therapies in advanced gastric cancer?

Pages : 11-15

View : 45 | Download : 10

Publication Date : 2015-09-30

Article Type : Research Paper

Abstract :Gastric cancer is the second most common cause of cancer related death worldwide. Over 20% of the advanced gastric cancer are considered to be HER-2 positive. Studies investigating the prognosis of HER-2 positive advanced gastric cancer revealed conflicting results. Trastuzumab, a monoclonal antibody against HER-2, has shown a significant clinical activity in HER-2 positive gastric cancer patients. In this review, I will briefly summarize the clinical studies of anti-HER-2 therapies performed in HER-2 positive gastric carcinoma. Keywords: Gastric cancer, HER-2/neu, Targeted therapy
Keywords : Gastric cancer, HER 2 neu, Targeted therapy

ORIGINAL ARTICLE URL

* There may have been changes in the journal, article,conference, book, preprint etc. informations. Therefore, it would be appropriate to follow the information on the official page of the source. The information here is shared for informational purposes. IAD is not responsible for incorrect or missing information.